Anonymous ID: 8519c6 May 25, 2020, 1:24 p.m. No.9312366   🗄️.is 🔗kun

>>9312060

>>9311804

>>9311942

Dr Raoult knows his stuff. A doc-friend of mine has worked with him in the past, says Raoult is brilliant. Here's another critique of the Lancet paper.

 

Dr. Steven phillips, MD debunks The Lancet's newest hit piece on HCQ

 

https://twitter.com/StevephillipsMD/status/1263899565654265857

 

Another poorly designed interpretation of a #HCQ data set for #COVID19. A larger poorly designed "trial" only leads to larger erroneous conclusions. For analysis, see the thread

 

 

Steven phillips, MD

@StevephillipsMD

May 23

The authors provide almost no data to assess disease severity at baseline between groups. They rely on qSOFA which in a study in Annals of Intensive Care, was found to be "…not appropriate to identify Covid-19 patients to have poor outcomes…" 👇

 

Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA

ncbi.nlm.nih.gov

 

Steven phillips, MD

@StevephillipsMD

May 23

And they don't say who got what other antiviral, grouping 3 different ones together. Big confounders. Except anyone who took remdesivir was excluded from the analysis. Why? Don't want to risk it being associated with a bad outcome in a faulty study?

 

Steven phillips, MD

@StevephillipsMD

May 23

I agree with one thing the authors said: "Randomized clinical trials will be required before any conclusion can be reached regarding benefit or harm of these agents in COVID-19 patients."

 

Actually, #HCQ RCT's have been done & they show benefits, but we need more of them.